Scienture Reports Preliminary Q3 Revenue Up 256% Sequentially to About $1.22 Million
Scienture said preliminary unaudited third-quarter revenue rose 256% sequentially to approximately $1.22 million, supported by Arbli growth and the commercial launch of REZENOPY. The company also highlighted two FDA-approved commercial products and progress toward profitability in 2027.